Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
Pyxis Oncology ( (PYXS)) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in ...
Investing.com - Pyxis Oncology Inc. (NASDAQ:PYXS) shares declined after RBC Capital lowered its price target to $5.00 from $8.00 while maintaining an Outperform rating. The adjustment follows Pyxis ...
BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...
For James Westlake, a recent Naked Wines campaign required a camera able to produce excellent images in a fast, lightweight, handheld setup, and the PYXIS 12K fit the bill. James Westlake is a UK ...
Maroussi, Greece – November 21, 2025 – Pyxis Tankers Inc. (the “Company”) (NASDAQ Cap Mkts: PXS), (the “Company”, “we”, “our”, “us” or ...
Maroussi, Greece, November 19, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international shipping company with a focus on the seaborne transportation of refined petroleum products and dry ...
Most camper van conversions we cover here on autoevolution are based on brand-new vans. However, a slightly older chassis works just as well and can help save you a decent amount of money. Today, I'm ...
Fintel reports that on November 4, 2025, Guggenheim maintained coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Buy recommendation. Analyst Price Forecast Suggests 60.63% Upside As of October 30, ...
HOUSTON, Sept. 19, 2025 /PRNewswire/ -- Pyxis Advisory Group, a diversified advisory firm serving the global industrial sector, has acquired Catule Consulting, effective September 1, 2025. As part of ...
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback